Metagenomi Therapeutics Total Assets 2022-2026 | MGX
Metagenomi Therapeutics total assets from 2022 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
|
Metagenomi Therapeutics Annual Total Assets (Millions of US $) |
|
|---|---|
| 2025 | $221 |
| 2024 | $325 |
| 2023 | $365 |
| 2022 | $414 |
| 2021 | $142 |
|
Metagenomi Therapeutics Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | $197 |
| 2025-12-31 | $221 |
| 2025-09-30 | $248 |
| 2025-06-30 | $272 |
| 2025-03-31 | $298 |
| 2024-12-31 | $325 |
| 2024-09-30 | $358 |
| 2024-06-30 | $386 |
| 2024-03-31 | $415 |
| 2023-12-31 | $365 |
| 2023-09-30 | $0 |
| 2023-06-30 | $0 |
| 2023-03-31 | $0 |
| 2022-12-31 | $414 |
| 2021-12-31 | $142 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |